Effects of ABCB1 gene polymorphisms on autonomic nervous system activity during atypical antipsychotic treatment in schizophrenia

BMC Psychiatry. 2018 Jul 17;18(1):231. doi: 10.1186/s12888-018-1817-5.

Abstract

Background: There are interindividual differences in the adverse effects of atypical antipsychotics, which include autonomic nervous system (ANS) dysfunction. Accordingly, to clarify the interindividual differences in the adverse effects of specific atypical antipsychotics in schizophrenia, we investigated the association between ANS dysfunction and ATP-binding cassette transport sub-family B member 1 (ABCB1) gene polymorphisms in patients with schizophrenia.

Methods: In total, 233 Japanese patients with schizophrenia participated in this study. All of the participants received an atypical antipsychotic as monotherapy: 89 participants received risperidone, 69 olanzapine, 48 aripiprazole, and 27 quetiapine. ANS activity was assessed by means of a power spectral analysis of heart rate variability. Four single nucleotide polymorphisms (SNPs) in ABCB1 (rs1045642, rs1128503, rs2032582, and rs2235048) were genotyped using the TaqMan method.

Results: For aripiprazole, sympathetic and total autonomic nervous activities were significantly lower in the rs1045642 T allele carrier-rs2235048 C allele carrier group than in the rs1045642 non-T allele carrier-rs2235048 non-C allele carrier group. In addition, in the aripiprazole group, the T-C-T-A haplotype (rs1045642-rs2235048-rs1128503-rs2032582) was associated with decreased ANS activity. However, there were no significant associations between ANS activity and ABCB1 gene polymorphisms in the risperidone, olanzapine, and quetiapine groups. Multiple regression analysis revealed that sympathetic and total nervous activities were significantly associated with the ABCB1 rs1045642-rs2235048 genotype and the T-C-T-A haplotype (rs1045642-rs2235048-rs1128503-rs2032582).

Conclusion: We suggest that ABCB1 genetic polymorphisms affect aripiprazole-related ANS dysfunction but do not affect risperidone-, olanzapine-, or quetiapine-related ANS dysfunction.

Keywords: ABCB1 gene; Atypical antipsychotic drug; Autonomic nervous system; Heart rate variability; P-glycoprotein; Schizophrenia.

MeSH terms

  • ATP Binding Cassette Transporter, Subfamily B / genetics
  • Adult
  • Aged
  • Antipsychotic Agents / adverse effects
  • Antipsychotic Agents / pharmacology
  • Antipsychotic Agents / therapeutic use*
  • Aripiprazole / adverse effects
  • Aripiprazole / pharmacology
  • Aripiprazole / therapeutic use
  • Autonomic Nervous System / drug effects
  • Autonomic Nervous System / physiology
  • Autonomic Nervous System / physiopathology
  • Cross-Sectional Studies
  • Female
  • Heart Rate / drug effects
  • Heart Rate / physiology*
  • Humans
  • Male
  • Middle Aged
  • Olanzapine / pharmacology
  • Olanzapine / therapeutic use
  • Polymorphism, Single Nucleotide / genetics*
  • Quetiapine Fumarate / adverse effects
  • Quetiapine Fumarate / pharmacology
  • Quetiapine Fumarate / therapeutic use
  • Risperidone / adverse effects
  • Risperidone / pharmacology
  • Risperidone / therapeutic use
  • Schizophrenia / drug therapy*
  • Schizophrenia / genetics*
  • Schizophrenia / physiopathology

Substances

  • ABCB1 protein, human
  • ATP Binding Cassette Transporter, Subfamily B
  • Antipsychotic Agents
  • Quetiapine Fumarate
  • Aripiprazole
  • Risperidone
  • Olanzapine